A Study to Evaluate the Efficacy and Safety of HAT01H in Atopic Dermatitis

Atopic Dermatitis Clinical Trial

Official title:

A Study to Evaluate the Efficacy and Safety of HAT01H, a Novel Topical Therapeutic: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial in Patients With Moderate to Severe Atopic Dermatitis

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03089229
• Other study ID #: HCTP17MD11
• Status: Completed
• Phase: Phase 1/Phase 2
• Start date: March 26, 2017
• Est. completion date: July 31, 2017

Study information

• Verified date: November 2018
• Source: Haus Bioceuticals
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Atopic dermatitis (AD) is a chronic inflammatory skin disease characterized by a disturbance of epidermal-barrier function that results in intensely pruritic subacute and chronic eczematous plaques. The current therapy of AD is reactive, where the flares are treated through symptomatic management with topical corticosteroids and calcineurin inhibitors. Given that these medications have long-term side-effects, and given the chronically relapsing immunopathogenic nature of AD, there is an imperative need for safer anti-inflammatory medications. Haus Bioceuticals (Haus) has developed a novel topical treatment for eczema/atopic dermatitis (AD) denoted HAT01H, and have demonstrated that HAT01H is safe and profoundly effective in the treatment of AD, controlling signs and symptoms in 85% of patients with AD. This study is aimed to further test the efficacy and safety of topical HAT01H in patients with moderate to severe atopic dermatitis.

Description:

This study is a 13 week (91 days) randomized, double-blind, in home use study among 30 male and female subjects with moderate to severe active atopic dermatitis (AD). The study will include subjects with ages 12 - 65 years old inclusive. Group assignments will be balanced by age and disease severity of AD. The study will consist of a 1 week washout period and 12 week treatment phase. During the treatment phase, subject will be provided one of the two test products to use twice daily on all lesions and non-lesional areas as instructed. No additional creams, lotions or soaps other than provided test products will be allowed throughout the duration of the study. Measurements, expert visual assessments and self-assessments will be taken as described below. Safety and tolerability will be evaluated by incidence of AE's (defined per CTCAE), exacerbations, application site reactions/infections, and lab evals. There will also be consumption/compliance checks and dermatological evaluations at each visit.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 30
• Est. completion date: July 31, 2017
• Est. primary completion date: June 30, 2017
• Accepts healthy volunteers: No
• Gender: All
• Age group: 12 Years to 65 Years

Eligibility

Inclusion Criteria:

• Moderate to severe atopic dermatitis as determined by PGA = 3 and SCORAD > 25

• Males and females, age 12 - 65 years old inclusive

Exclusion Criteria:

• Is currently participating or has participated in another interventional clinical study at this or any other facility in the past 3 months.

• Currently or has been diagnosed or treated for cancer in the past 5 years.

• Requires any topical or systemic medications that could affect the course of their atopic dermatitis during the study period (except inhaled steroids and/or stable antihistamines for asthma or allergies).

• Has a known hypersensitivity to any corticosteroid creams.

• Has any active infections or has used antibiotics in the past 7 days.

• Has any physical attributes or skin conditions that might interfere with clear visual assessments (i.e. cuts, sunburn, birth marks, tattoos, extensive scarring, excessive hair growth or acne)

• Has an immunologic or infectious disease (e.g. hepatitis, tuberculosis, HIV or AIDS, lupus, rheumatoid arthritis) which could place the subject at risk or interfere with the accuracy of the study results.

• Has used any immunosuppressant drugs or immunotherapy within the past 30 days or 5 half-lives.

• Is an employee of the sponsor company or clinical testing site.

• Is dependent on oral medication for any skin disease/condition or could not, in the opinion of the Investigator tolerate the restriction of discontinuing the medicine as required in this study.

• Is currently pregnant or lactating or planning to become pregnant in the next 6 months (using double contraception for prevention).

• Any other condition or factor the Investigator or their duly assigned representative believes may affect the ability of the subject to complete the study or the interpretation of the results.

Related Conditions & MeSH terms

• Atopic Dermatitis
• Dermatitis
• Dermatitis, Atopic
• Eczema

Intervention

Drug:
• HAT01H Cream
HAT01H Cream will be applied twice daily. The research team will provide instructions for the correct application of the treatment. If a lesion disappears, patients will continue applying the cream twice daily to the area. No additional creams, lotions or soaps other than provided test products will be allowed throughout the duration of the study.
• Vehicle Cream
Vehicle Cream will be applied twice daily. The research team will provide instructions for the correct application of the treatment. If a lesion disappears, patients will continue applying the cream twice daily to the area. No additional creams, lotions or soaps other than provided test products will be allowed throughout the duration of the study.

Locations

Country	Name	City	State
India	Clinical Research Pvt Ltd	Bangalore	Karnataka

Sponsors (1)

Lead Sponsor	Collaborator
Haus Bioceuticals

Country where clinical trial is conducted

India, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Change in Scoring of Atopic Dermatitis (SCORAD) score	The primary efficacy is determined by absolute change from baseline to week 12 in inflammatory SCORAD.	Baseline to week 12
Secondary	Proportion of patients achieving a Physician's Global Assessment (PGA) score of 0 or 1	The secondary efficacy measures is determined by absolute change from baseline to week 12 in PGA	Baseline to week 12
Secondary	Incidence of treatment emergent Adverse Event	The secondary efficacy measures also include safety and tolerability (incidence of treatment emergent AE's)	Baseline to week 12